Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the health-check domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /dom76025/wp-includes/functions.php on line 6121
May 6, 2024 - The Dermatology Digest
Subscribe
Search

Day: May 6, 2024

AD Pipeline Watch: Inmagene’s Anti-OX40 Monoclonal Antibody Performs Well in Phase 2a AD Trial

Treatment with Inmagene Biopharmaceuticals’ anti-OX40 monoclonal antibodyled to “rapid, marked, and durable” improvements of skin signs in in a Phase 2a trial of patients with atopic dermatitis (AD) IMG-007 is a non-depleting anti-OX40 mAb, bioengineered to have a silenced antibody-dependent cellular cytotoxicity (ADCC) function and a prolonged half-life. The Phase 2a trial (NCT05984784) evaluates the […]